“Plexxikon – 2010 Fierce 15” – FierceBiotech
September 15, 2010
With pharma focused on new frontline therapies, developers are relying on new technology to advance a fresh series of best-in-class therapies–anything that looks like a me-too approach won’t get pushed. And Plexxikon hit paydirt when it collected a $60 million upfront from Roche in early 2009 pact covering its PLX-5568, an experimental therapy for a rare genetic kidney disease as well as additional undisclosed programs. Altogether the developer has rounded up a whopping $185 million in non-dilutive partnership funding, a stellar record in an industry that thrives on that kind of cash.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.